Blacksburg, Va., Aug. 23, 2004 -- An enzyme called Pin1, a gatekeeper of cell division, is present at high levels in a wide variety of cancer cells. Virginia Tech researchers who are designing small molecules to inhibit Pin1 are seeing promising results with a small U-shaped molecule.
Felicia Etzkorn, associate professor of chemistry, will report on her group's achievements in presentations at the 228th American Chemical Society (ACS) National Meeting in Philadelphia August 22-26.
Pin1 regulates the protein Cdc25, which initiates mitosis or cell division. Without Pin1, the cell enters programmed cell death -- which is good if it's a cancer cell.
"It makes sense to inhibit the Pin1 enzyme," said Etzkorn.
Protein shape determines biological function. Pin1 works by changing a peptide bond within Cdc25 from the trans shape (a flattened-Z shape) to the cis U-shape and back. This a simple change -- the swing of an arm one way or another to open or close the U – results in a large conformation change in a protein.
The researchers synthesized cis and trans shaped inhibitors and introduced them into cancer cells. These inhibitors mimic part of the Cdc25 protein but do not bend to the will of Pin1. The research team discovered that cis inhibits the Pin1 enzyme's function 23 times better than trans. "This is very exciting because it tells us something fundamental about the mechanism.
The Etzkorn group tested the inhibitors in an ovarian cancer cell line. "That was the cell line that was available, but it should work for many cancers," Etzkorn said. "It would probably be particularly effective against breast cancer and prostate cancer. It seems to relate to secondary sexual characteristics."
However, a lot of work remains to be done to develop a drug, she cautions. "For instance, the inhibitor does not cross cell membranes. We can overcome that in the laboratory in order to study effectiveness, but have not done animal trials."
Etzkorn concludes, "We are moving closer to validating Pin1 as an anti-cancer target. There is now a small community of scientists looking at inhibiting Pin1, but once it is validated as a target, more researchers will step in."
Etzkorn's talk, "Protein mimics inhibit enzymes that regulate the cell cycle," will be presented at the Division of Organic Chemistry's Women in Organic Synthesis symposium at 10:30 a.m., Monday, Aug. 23, in Ballroom A of the Pennsylvania Convention Center.
The poster, "PhosphoSer-cis-Pro isostere inhibits Pin1 23-fold better than the trans-Pro isostere," by Etzkorn, PhD. student Xiaodong Jane Wang, post-doctoral associate Bailing Xu, former undergraduate Freda K. Neiler, and master's candidate Ashley B. Mullins, all of the Virginia Tech Department of Chemistry, will be presented at the Division of Medicinal Chemistry poster session, 6 to 8 p.m., Sunday, Aug. 22, in Hall D of the Pennsylvania Convention Center.
The poster, " Inverse secondary deuterium isotope effect in Pin1 proline isomerization," by Etzkorn, Mullins, and former chemistry laboratory technician Matthew D. Mason, will be presented at the Protein Function, Enzymology, Heme Biochemistry poster session of the Division of Biological Chemistry, noon to 2 p.m., Tuesday, Aug. 24, Halls A and B of the Pennsylvania Convention Center.
Wang, whose master's degree is from NanKai University, Tianjin, China, is doing her Ph.D. research on inhibiting Pin1. Mullins, of Grundy, Va., is doing her master's research on understanding how Pin1 works. She purified the protein for this research. Neiler, of Fairfax, Va., received her undergraduate degree in human nutrition, foods, and exercise from Virginia Tech and enrolled in the School of Pharmacy at the Medical College of Virginia. She did the ovarian cell based assays for the Etzkorn group research. Mason. who made the protein substrates, is now starting the M.D. program at SUNY Upstate Medical University in Syracuse, N.Y.
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.
It is never too late to be what you might have been.
-- George Eliot